Conference Description:

The Chronic Kidney Disease Drug Development Summit is industry’s first end-to-end drug development networking and discussion forum, dedicated to overcoming challenges drug developers face in developing chronic kidney disease therapeutics more efficacious than the current standard of care.

Developed in combination with experts from Boehringer Ingelheim, Bayer, Astrazeneca, Johnson & Johnson and many more, this industry focused forum focuses on lessons learnt from CKD drug development failures, molecular understanding and reclassification towards comprehensive precisions medicine and the potential of next generation therapeutics to deliver efficacy above and beyond angiotensin converting enzyme (ACE) inhibitors and ALT1 receptor antagonists (ARBs).

Be part of the cross-industry discussions set to benchmark the next wave of progress in CKD therapeutic development. Leave CKD3 with a deeper understanding of underlying molecular pathology drivers, advancements in patient stratification to optimize clinical trials, the latest data for next generation therapeutics and the reality of these therapeutics achieving a pharmacoeconomic benefit in the clinic.

Brochure https://go.evvnt.com/193286-1?pid=154
Booking https://go.evvnt.com/193286-2? pid=154

Prices:
Earlybird Conference Price: USD 2499
Standard Conference Price: USD 2799

Speakers: Matthew Breyer (Eli Lilly & Co), Christina Nowack (Bayer), Caroline Fox (Merck), Maria-Chiara Magnone (AstraZeneca)

Time: on Monday May 21, 2018 at 9:00 am (ends Wednesday May 23, 2018 at 6:00 pm)